Vigil Neuroscience has a total of 43 patents globally, out of which 1 has been granted. Of these 43 patents, more than 93% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Vigil Neuroscience.
Vigil Neuroscience was founded in the year 2020. The Company operates as a biotechnology company. The Company focuses on discovering and developing novel therapeutics in basic science and human genetics of microglia. As of May 2023, the market cap of Vigil Neuroscience is $356.67 Million.
Do read about some of the most popular patents of Vigil Neuroscience which have been covered by us in this article and also you can find Vigil Neuroscience patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Vigil Neuroscience patent portfolio.
How many patents does the CEO of Vigil Neuroscience have?
The CEO Ivana Magovčević-Liebisch has 0 patent.
How many patents does Vigil Neuroscience have?
Vigil Neuroscience has a total of 43 patents globally. These patents belong to 9 unique patent families. Out of 43 patents, 40 patents are active.
How Many Patents did Vigil Neuroscience File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Vigil Neuroscience Applications Filed | Vigil Neuroscience Patents Granted |
| 2023 | 1 | 1 |
| 2022 | 14 | – |
| 2021 | 28 | – |
How many Vigil Neuroscience patents are Alive/Dead?
How Many Patents did Vigil Neuroscience File in Different Countries?
Countries in which Vigil Neuroscience Filed Patents
| Country | Patents |
| Taiwan | 3 |
| South Africa | 3 |
| Australia | 3 |
| United States Of America | 3 |
| Brazil | 3 |
| Canada | 3 |
| Africa | 3 |
| Ecuador | 2 |
| India | 2 |
| Colombia | 2 |
| New Zealand | 2 |
| Mexico | 2 |
| Singapore | 2 |
| Israel | 2 |
| Argentina | 1 |
| Indonesia | 1 |
Where are Research Centres of Vigil Neuroscience Patents Located?
What Percentage of Vigil Neuroscience US Patent Applications were Granted?
Vigil Neuroscience (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0.0%.
Below are the key stats of Vigil Neuroscience patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Vigil Neuroscience?
| Law Firm | Total Applications | Success Rate |
| Dechert | 2 | 0% |
List of Vigil Neuroscience Patents
| Vigil Neuroscience Patents | Title |
| US11608344B2 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| US20230082623A1 | Treatment Of Diseases Related To Atp-Binding Cassette Transporter 1 Dysfunction Using Trem2 Agonists |
| US20220089726A1 | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| WO2022236272A3 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| WO2022251868A1 | Trem2 Agonist Biomarkers And Methods Of Use Thereof |
| WO2022120390A1 | Treatment Of Diseases Related To Atp-Binding Cassette Transporter 1 Dysfunction Using Trem2 Agonists |
| WO2022032293A3 | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| WO2021226135A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| WO2021226629A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| BR112023002093A2 | Treatment Of Diseases Related To Colony Stimulating Factor 1 Receptor Dysfunction Using Train2 Agonists |
| AU2021320553A1 | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| TW202309029A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| APP2023014673A0 | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Tremm2 Agonists |
| ZA202301372A | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| BR112022022338A2 | Heterocyclic Compounds As An Express Trigger Receptor In Myeloid 2 Cell Agonists And Methods Of Use |
| BR112022022341A2 | Heterocyclic Compounds As An Express Trigger Receptor In Myeloid 2 Cell Agonists And Methods Of Use |
| APP2022014529A0 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| APP2022014530A0 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| AU2021267161A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| AU2021266805A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| ZA202211897A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| ZA202211896A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| TW202218683A | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| TW202208355A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| CA3190581A1 | Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists |
| CA3182105A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| CA3182541A1 | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| MX2022013838A | Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed On Myeloid Cells 2 And Methods Of Use |
| MX2022013842A | Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed On Myeloid Cells 2 And Methods Of Use |
| ECSP22089520A | Heterocyclic Compounds As Trigger Receptors Expressed In Myeloid Cell 2 Agonists And Methods Of Use |
| ECSP22089527A | Heterocyclic Compounds As Trigger Receptors Expressed In Myeloid Cell 2 Agonists And Methods Of Use |
| IN202217062928A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| IN202217062929A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| CO20220015927A2 | Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed In Myeloid Cells 2 And Methods Of Use |
| CO20220015930A2 | Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed In Myeloid Cells 2 |
| SG11202254287BA | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| SG11202254290MA | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| NZ793874A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| NZ794078A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| ID202301905A | Heterosyclic Compounds As Trigger Receptors Expressed In Mieloid 2 Cell Agonists And Methods Of Their Use |
| IL297833A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| IL297845A | Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use |
| AR122010A1 | Heterocyclic Compounds As Trigging Receptors Expressed In Myeloid 2 Cell Agonists And Methods Of Use |